ALZHEIMERS DISEASE

Introduction

  • Neurodegenerative Disease

    • Characterized by memory or cognitive loss.

    • Millions affected, predominantly older patients but can occur in any age group.

    • Progressive illness leading to loss of cognitive, physical, and behavioral functions.

    • Often initiated by multiple health problems.

    • Mild cognitive impairment (MCI) frequently precedes dementia, but progression to dementia is not guaranteed.

  • Alzheimer's Disease (AD)

    • Most common form of dementia; progressively impacts cognition, behavior, and functional abilities.

    • Genetic susceptibility plays a role in etiopathogenesis; late-onset AD linked to Apolipoprotein E (ApoE).

    • Environmental interactions can trigger AD.

    • Currently, no cure exists; only symptomatic treatment.

    • 1% chance for younger populations to develop AD.

    • Associated with chromosomal aberrations unclear as of now, but amyloid proteins in the brain are considered a hallmark of AD.

Risk Factors for AD

  1. Age

  2. CT or MRI evidence of brain shrinkage or atrophy, indicating decreased brain reserve capacity.

  3. Down syndrome.

  4. Depression.

  5. Mild Cognitive Impairment (MCI).

  6. Lipid abnormalities, especially elevated homocysteine levels.

  7. Metabolic syndrome (e.g., diabetes).

  8. History of stroke.

Pathophysiology of AD

  • Signature lesions upon brain dissection: amyloid plaques and intracellular neurofibrillary tangles (NFTs) found primarily in the temporal lobe (critical for memory).

  • Atrophy evident via CT scans or MRIs with progression severity correlating to plaque quantities.

  • Mechanisms for NFT and amyloid formation:

    1. Accumulation of beta-amyloid protein.

    2. Hyperphosphorylation of TAU proteins leads to NFTs.

    3. Depletion of brain-derived neurotrophic factors and neurotransmitters.

    4. Possible mitochondrial dysfunction and oxidative stress involvement.

  • Loss of cholinergic activity also implicated; diminished acetylcholine (Ach) and other neurotransmitters contribute to decline.

Early Signs of AD

  • Memory loss or forgetfulness.

  • Impaired judgment.

  • Disorientation in some patients.

Late Stages of AD

  • Rare behaviors manifest.

  • Patients unable to perform self-care.

Stage Assessment of AD

  • Mini-Mental State/Status Examination (MMSE) scoring system:

    1. Mild.

    2. Moderate.

    3. Severe (significant functional impairment).

Diagnosis of AD

  • Challenging due to symptomatic onset occurring during the preclinical phase.

  • CT and MRI are not reliable for definitive diagnosis; serve as adjunct to clinical evaluations.

  • Diagnosis conducted via patient history and physical exams aiming to rule out mimicking diseases.

  • Often categorized as a “waste basket disease,” diagnosed when other causes are excluded.

  • Key diagnostic indicators:

    • Amyloid plaques via CT scans.

    • Brain atrophy indicated by increased space between brain and skull.

    • CSF testing unable to diagnose AD directly.

    • Genetic studies focusing on ApoE and amyloid plaque formation offer diagnostic support.

Considerations for Pharmacists

  1. Assess for substance abuse to avoid misdiagnosis.

  2. Review history for head trauma or injuries.

  3. Evaluate medication use:

    • Anticholinergics.

    • Sedatives.

    • Opioids.

    • Antipsychotics.

    • Anticonvulsants.

  4. Be aware of potential drugs leading to delirium:

    • NSAIDs.

    • H2 receptor blockers.

    • Antihypertensives.

    • Antiarrhythmic drugs (e.g., amiodarone).

    • Corticosteroids.

Goals of Treatment for AD

  1. Preserve cognitive functioning and quality of life via engaging activities (e.g., crossword puzzles).

  2. Address and manage behavioral issues stemming from AD, potentially leading to psychiatric challenges.

Non-Pharmacologic Strategies

  1. Investigate and address potential causes of forgetfulness (e.g., Vitamin B12 deficiency).

  2. Create a stimulating home environment supporting the patient's cognitive function.

  3. Educate about managing sleep disturbances and incontinence.

  4. Identify triggers for symptoms indicative of AD.

Pharmacologic Treatments (Trial and Error)

  • No guaranteed pharmacologic interventions; treatment efficacy varies per individual.

Pharmacological Management Options

  1. Anti-Amyloid Monoclonal Antibodies

    • Promising but still in development; shows potential to slow AD progression.

    • Goal: destroy or prevent amyloid plaque formation.

    • Examples: Aducanumab, Lecanemab, Donanemab, Gantenerumab.

  2. Cholinesterase Inhibitors

    • Effective for mild to moderate AD: -stigmine, Donepezil, Rivastigmine, Galantamine.

  3. Antiglutamatergic Therapy / NMDA Receptor Agonist

    • NMDA (N-methyl-D-aspartate) receptor involved in glutamate transmission.

    • Memantine recommended for moderate to severe AD; can be combined with cholinesterase inhibitors to yield modest cognitive improvements.

    • Memantine is the only NMDA receptor antagonist approved for AD treatment.

Medication Management Considerations

  • Employ MMSE scoring to gauge therapeutic efficacy; adjust dosages accordingly, starting with lower doses.

  • Consider hormonal replacement therapy for menopause effects contributing to AD.

  • Additional compounds: NSAIDs, corticosteroids, statins, nutritional supplements (e.g., Ginkgo Biloba, Vitamin E, Omega-3 fatty acids).

Genetic Factors

  • Family history of AD complications warrants closer observation (e.g., both grandparents with AD).

  • Psychiatric manifestations may arise; cautiously consider antipsychotic treatment.

  • If depression is noted, case-by-case analysis directs the use of antidepressants.

Treating Associated Psychiatric Symptoms

  • Employ SSRIs judiciously for extended periods when addressing depression or anxiety linked to AD.

  • Consider mood stabilizers; anticonvulsants may serve as alternatives to lithium in managing bipolar symptoms.

Conclusion

  • Always evaluate patients utilizing MMSE assessments.

  • Understand the absence of curative treatment while recognizing that current drugs may help mitigate AD progression.

  • AD represents a continuous neurodegenerative process, culminating in cognitive, psychological, and behavioral deterioration; careful management is essential.